Newcastle University

Introduction

Professor of Experimental Cancer Therapeutics since 2006. Team leader for DNA damage signalling and repair projects within CR-UK Drug Development Programme

Roles and Responsibilities

Manage Drug Development Laboratory in NICR DNA damage signalling and repair and cell cycle projects
Liase with other groups within NICR and with other academic and industrial parteners on a variety of projects
Career Pathway Advisor

Qualifications

1975 B.A. Biology, University of York
1977 M.Sc. Manchester University
1981 Ph.D. University of Surrey

Previous Positions

1982-1985 RA PHLS Newcastle upon Tyne
1985-1990 RA Cancer Research Unit (CRU), University of Newcastle upon Tyne
1990-1996 SRA,CRU

Memberships

British Association for Cancer Research
BACR Executive Committee
American Association for Cancer Research

Research Interests

Evaluation of novel therapeutics for cancer, particularly
a) Inhibitors of the DNA repair enzymes poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase (DNA-PK) and ATM to increase the efficacy of DNA damaging anticancer agents.
b) Investigation of the synthetic lethality of these inhibitors in cancer cells with defects in DNA damage signalling and repair pathways.
c) Inhibitors of cyclin dependent kinases (CDKs)to arrest the growth of tumour cells, particularly as a means to overcome hormone therapy resistance in breast and prostate cancer.

Other Expertise

a) Antifolates.
b)Inhibitors of nucleoside and nucleobase transport .

Current Work

Preclinical evaluation of PARP, ATM and DNA-PK inhibitors as chemo and radiosensitisers in models of adult and childhood cancer, and the mechanisms underlying sensitisation.
Investigation of the effects of PARP inhibition in DNA repair-defective cells (esp BRCA2 defective)
Investigation of tumour drug delivery
Investigation of novel pyrimido-pyrimidines as anticancer agents
Investigation of novel CDK inhibitors and their role in hormone refractory breast and prostate cancer.

Future Research

Investigation of the therapeutic potential of ATR inhibition.
Investigation of the interaction of CDK inhibitors with conventional cytotoxic agents.

Research Roles

Team Leader for Drug Development Bioscience projects on DNA damage signalling and repair

Postgraduate Supervision

Supervision of PhD students and Clinical Fellows:
Karen Bowman PhD 1993-1997 NECRC "Evaluation of novel compounds to modulate the cytotoxicity of anticancer agents in mammalian cells"
Mike Roberts PhD 1994-1998 NECRC ADPRT inhibitor cytotoxicity
Emma Marshman PhD 1995-1998 CRC The development of selective antifolate therapy for solid tumours
Noel Monks PhD 1995-1998 AstraZeneca Studies on resistance mechanisms in ADEPT
Peter Smith PhD 1996-1999 Eli Lilly Nucleoside transport inhibitors to potentiate antifolate GARFT and TS inhibitors
Stephany Veuger PhD 1999-2003 CRC An investigation into the interactive effects of poly(ADP-ribose) polymerase and DNA-dependent protein kinase in cellular response to DNA damage
Lisa Smith PhD 2000-2003 CRC Investigation of the role of poly(ADP-ribose) polymerase (PARP) in the cellular response to topoisomerase I poisons
Neil Johnson PhD 2002-2006 Breast Cancer Campaign Investigation of the therapeutic potential of novel CDK inhibitors in breast cancer
Jody Mitchell PhD 2003-2007. BBSRC Industrial Case. Interaction of Poly(ADP-ribose) polymerase-1 (PARP-1) and DNA-dependent protein kinase (DNA-PK) in the repair of DNA double-strand breaks induced by ionizing radiation (IR)
Chris Jones MD 2003-2006. CR-UK. Phase I trial of PARP inhibitor AG014699 in combination with temozolomide
Vijay Sujendran MD 2003 Based in Oxford, main supervisor M Middleton DNA repair enzymes in oesophageal and gastric cancer treated with platinum an 5-FU
Tomasz Zaremba PhD 2006-2009 AICR
Poly(ADP-ribose) polymerase pharmacogenetics and expression analysis in patients receiving anticancer therapy.
Pawel Znojek PhD 2006-2010
Investigation of the role of poly(ADP-ribose) polymerase (PARP) inhibition in topoisomerase I (topo I) poison-induced cytotoxicity

Esteem Indicators

Member of Breast Cancer Campaign Scientific Committee
Member of Tynside Leukaemia Research Association Scientific Committee
Member of Newcastle NHS Joint Research Executive
Invited speaker at National and International Meetings
Invited to write Review articles
Review manuscripts submitted to high impact journals
Review grant applications

Funding

CURRENT FUNDING
Poly(ADP-ribose) polymerase pharmacogenetics and expression analysis in patients receiving anticancer therapy. NJ Curtin (PI), ER Plummer, SA Coulthard, M Cole. AICR £77,510 01/04/06-31/03/09
Proposal for addition of pharmacodynamic sampling to AG014699/temozolomide phase II study. ER Plummer (PI) and NJ Curtin. Pfizer £131,280 01/03/06-29/02/08
Investigation of the role of poly(ADP-ribose) polymerase (PARP) inhibition in topoisomerase I (topo I) poison-induced cytotoxicity NJ Curtin (PI) and E Willmore. CR-UK 01/10/2006-30/9/2010
Assessment of PARP1, DNA-PK and ATM inhibitors as chemo-potentiating agents in medulloblastoma and neuroblastoma. S. Clifford (PI), NJ Curtin, AV Boddy D Tweddle. CR-UK Development Committee. £209,852 01/02/05 – 31/01/07
PREVIOUS FUNDING
Preclinical evaluation of DNA-PK and ATM inhibitors (extension). N.J. Curtin (PI) D.R. Newell, H. Thomas. KuDos Pharmaceuticals £108,588 01/01/06-31/12/06 12 months
Novel Pyrimidopyrimidine-based Nucleoside Transport Inhibitors (extension) N.J. Curtin (PI) BT Golding, RJ Griffin, AH Calvert and DR Newell. CR-UK Development Committee. £37,000 01/04/05 – 30/09/05
Preclinical evaluation of ATM and DNA-PK inhibitors (2nd extension). N.J. Curtin (PI) D.R. Newell, H. Thomas. KuDos Pharmaceuticals £85,000 01/06/05-31/05/06 12 months
Investigation of Chemosensitization of Cisplatin by PARP inhibitors in vivo. N.J. Curtin (PI), AV Boddy and MJ Tilby. Pfizer £124,265 01/01/05-31/12/05
Preclinical evaluation of DNA-PK and ATM inhibitors (extension). N.J. Curtin (PI) D.R. Newell, H. Thomas. KuDos Pharmaceuticals £105,583 01/01/05-31/12/05 12 months
Preclinical evaluation of ATM and DNA-PK inhibitors (extension). N.J. Curtin (PI) D.R. Newell, H. Thomas. KuDos Pharmaceuticals £85,470 01/06/03-31/05/05 12 months
Novel Pyrimidopyrimidine-based Nucleoside Transport Inhibitors N.J. Curtin (PI) BT Golding, RJ Griffin, AH Calvert and DR Newell. CR-UK Development Committee. £59,000 01/04/04 – 31/03/05
Interaction of Poly(ADP-ribose) polymerase-1 (PARP-1) and DNA-dependent protein kinase (DNA-PK) in the repair of DNA double-strand breaks induced by ionizing radiation (IR) N.J. Curtin (PI) and G.C.M. Smith (industrial supervisor) BBSRC Industrial Case £67,860 01/10/03 – 30/09/06
Investigation of the therapeutic potential of novel CDK inhibitors in prostate cancer. N.J. Curtin (PI) and C.N. Robson. Association for International Cancer Research. £83,545. 01/10/03 -30/09/05 24 months
Preclinical evaluation of DNA-PK and ATM inhibitors. N.J. Curtin (PI) D.R. Newell, H. Thomas. KuDos Pharmaceuticals £198,917 01/01/03-31/12/04 24 months
Clinical research Fellow for a Phase I trial of PARP inhibitor AG14699 in combination with temozolomide. N.J.Curtin (PI), AH Calvert, ER Plummer. CRUK/ Agouron Pfizer £166,410 Oct 2002-OCT.2004 (2 years)
Temozolomide-induced DNA damage in advanced malignant melanoma. AH Calvert (PI), ER Plummer, NJ Curtin, DR Newewll, AV Boddy, M Midleton and R Wilson. Agouron Pfizer Inc. £80,371. July 2002-Jan 2003 (6 months).
Development of pharmacodynamic assays for the clinical evaluation of novel PARP inhibitors, and pre-clinical investigations of backup compounds N.J.Curtin (PI), AH Calvert, DR Newell, AV Boddy and BW Durkacz. Agouron Pfizer Inc. £62,226. Jan 2002-July 2002 (6 months).
Design, synthesis and evaluation of novel CDK inhibitors. NJ Curtin (PI) AH Calvert, DR Newell, RJ Griffin, BT Golding and IR Hardcastle. AstraZeneca: £100,000. 2002-2003
Investigation of the therapeutic potential of novel CDK inhibitors in breast cancer. NJ Curtin (sole investigator). Breast Cancer Campaign: £63,550. Oct 2002-Oct 2005
Preclinical and pharmacodynamic studies with Novel DNA-PK inhibitors. NJ Curtin (PI) AH Calvert, BW Durkacz, DR Newell, RJ Griffin, BT Golding and IR Hardcastle. KuDos Pharmaceuticals £183,394 Jan 2002-Dec 2003.
Application for a Clinician Scientist with responsibility for early clinical studies of new anti-leukaemic agents in children. PR Kearns (P.I.), A. Boddy, S. Coulthard, NJ Curtin, AG Hall, DR Newell, ADJ Pearson. Leukaemia Research Fund, £257,388" 2001-2004
Development of pharmacodynamic assays for the clinical evaluation of novel PARP inhibitors, and pre-clinical investigations of backup compounds Agouron Pfizer Inc. £107,500. Jan 2001-Jan 2002 (1 year). N.J.Curtin (PI), AH Calvert, DR Newell, AV Boddy and BW Durkacz
Crystal structure-based design of novel inhibitors of poly(ADP-ribose)polymerase." N.J. Curtin (PI) AH Calvert, BT Golding,RJ Griffin and DR Newell. Agouron Pharmaceuticals Inc. £218,060. Jan 2000- 2001 (1 year)
"Investigation of the role of poly(ADP-ribose) polymerase (PARP) in the cellular response to topoisomerase I poisons" NJ Curtin (PI) C. Austin. CRC Cancer Research Unit award £58,000 Oct 2000 - 2003 (3 years)
"Structure-based design, synthesis and evaluation of inhibitors of cyclin-dependent kinases" D.R. Newell (PI), A.H. Calvert, NJ Curtin, B.T. Golding and L. Johnson and Drs. R.J. Griffin, J. Endicott and M. Noble. MRC-AstraZeneca LINK £400,000. Nov 1999-2002 (3 years)
"An investigation into the interactive effects of poly(ADP-ribose) polymerase and DNA-dependent protein kinase in cellular response to DNA damage." B.W. Durkacz (PI) and NJ Curtin. Cancer Research Campaign. £56,520 Oct.1999-2002 (3 years)
"Design and synthesis of inhibitors of DNA-dependent protein kinase." RJ Griffin (PI) AH Calvert, NJ Curtin, BW Durkacz, BT Golding, DR Newell. Cancer Research Campaign £46,000 Oct.1998 -2001 (3 years).
"Novel inhibitors of cyclin-dependent kinases" RJ Griffin AH Calvert, NJ Curtin BT Golding, DR Newell. Cancer Research Campaign. £41,400. Oct.1998-2001 (3 years).
Cancer Research Unit Programme Grant. AH Calvert (PI), AV Boddy, NJ Curtin BW Durkacz, J Lunec and DR Newell Cancer Research Campaign £5,000,000. 1997-2002 (5 years)
"Novel inhibitors of poly(ADP-ribose)polymerase." RJ Griffin (PI) AH Calvert, NJ Curtin, BT Golding, DR Newell The North of England Cancer Research Campaign. £41,400.Oct 1997 -2000 (3 years).
"Clinical-laboratory study to define determinants of the activity of LY309887 in patients with head and neck, and breast, cancer" DR Newell (PI), A Boddy, AH Calvert, NJ Curtin, J Lunec and GA Taylor. Eli Lilly and Co. £253,998. Nov. 1997-2000 (3 years).
"Crystal structure-based design of novel inhibitors of poly(ADP-ribose)polymerase." RJ Griffin, and NJ Curtin (Joint PI) AH Calvert, BT Golding and DR Newell Agouron Pharmaceuticals Inc. £531,956. Nov. 1997-1999 (2 years).
"Application of Combinatorial Organic Synthesis to the development of Novel Nucleoside Transport Inhibitors" BT Golding (PI), NJ Curtin and Dr RJ Griffin. North of England Cancer Research Campaign. £40,400 Oct 1996-1999 (3 years).
"Development and preclinical evaluation of nucleoside and nucleobase transport inhibitors to potentiate antifolate GARFT and TS inhibitors" NJ Curtin (PI) A.H. Calvert, B.T. Golding, R.J. Griffin and D.R. Newell. Eli Lilly and Co. £48,025. Oct. 1996-1999 (3 years).
"Activity of cytotoxic drugs - potentiation by PARP inhibitors". RJ Griffin (PI) AH Calvert, NJ Curtin, BT Golding and DR Newell Agouron Pharmaceuticals. £17,000 Sept 1996 - Mar 1997 (0.5 years)
"The development of selective antifolate therapy for solid tumours" NJ Curtin (PI) A.H. Calvert and D.R. Newell. Cancer Research Campaign. £45,990, Oct 1995-1998 (3 years).
"Inhibitors of cyclin-dependent protein kinases as potential cancer chemotherapeutics" RJ Griffin (PI) AH Calvert, NJ Curtin, BT Golding and DR Newell North of England Cancer Research Campaign. £42,000, Oct. 1995-1998 (3 years).
"ADPRT inhibitor cytotoxicity" DR Newell (PI) NJ Curtin, B. W. Durkacz and A. G. Hall. North of England Cancer Research Campaign. £40,300, Oct 1994-1997 (3 years).
"Inhibitors of methionine synthase" B.T. Golding (PI), AH Calvert, NJ Curtin, R.J. Griffin, D.R. Newell and Prof. A.H. Calvert. EPSRC£149,739, Oct 1994-1997 (3 years).
"Studies on the potentiation of cytotoxic drugs by dipyridamole and novel analogues." NJ Curtin (PI) North of England Childrens Cancer Research Fund. £1,370 Sept 1993-1994 (1 year).
"The development and evaluation of inhibitors of the repair protein methylguanine methyltransferase" C. Bleasdale (PI), AH Calvert, NJ Curtin, B.T. Golding, R.J. Griffin and D.R. Newell. Zenecca pharmaceuticals. £35,000, Oct. 1993-1997 (3 years).
"The development of inhibitors of poly(ADP-ribose)polymerse and nucleoside transport to potentiate the activity of cytotoxic drugs." RJ Griffin (PI) C Bleasdale, A.H. Calvert, NJ Curtin, BT Golding, RJ Griffin and D.R. Newell. North of England Cancer Research Campaign. £72,000 Oct 1993-1996 (3 years).
"The synthesis and evaluation of novel antitumour agents" AH Calvert (PI) C. Bleasdale, NJ Curtin, B.T. Golding and Dr. D.R. Newell. North of England Cancer Research Campaign. £300,000. Oct 1990-1993 (3 years)
"Thymidylate synthase (TS), a target for chemotherapy: mechanism of cell killing by TS inhibition with relation to dUTP and uracil glycosylase." Oct 1985 -Oct 1990. Joint holder with Prof A.L. Harris Oct 1985- Oct 1989 and with Prof. A.H. Calvert Oct 1989 - Oct 1990. North of England Cancer Research Campaign.

Industrial Relevance

Several of the current and past projects are in collaboration with or have been funded by the Pharmaceutical Industry.

Patents

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., and Golding, B. T. Benzamide Analogues ADPRT (PARP) Inhibitors
Patent Application Number PCT/GB95/00513 (1995)

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Benzimidazole PARP Inhibitors.
Patent Application Number PCT/GB96/01832.

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Prodrugs of PARP Inhibitors.
Patent Application Number PCT/GB97/02701.5

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Pyrimidopyrimidine Compounds
Patent Application Number PCT/GB97/06618.7.

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T., Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Purine CDK Inhibitors.
Patent Application Number PCT/GB97/14603.9

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Pyrimidine CDK Inhibitors.
Patent Application Number PCT/GB98/06739.0

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. and Golding, B. T. Dipyridamole analogues
Patent Application Number PCT/GB98/00966

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R. Golding, B. T., Hardcastle I, Endicott, J.A., Noble, M.E.M., Boyle, F.T. and Jewsbury, P.J. Anilinopurine CDK Inhibitors.
Patent Application Number PCT/GB01/01686.4

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. DNA-PK inhibitors - 1
Patent Application Number PCT/GB01/19865.4 GB/14.08.01/GBA0119865

Griffin, R. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Golding, B. T. Hardcastle, I.R., Martin, N., Smith, G.C.M., Raynaud, F. and Workman, P. Thiopyran-4-ones as DNA-PK inhibitors
Patent Application Number PCT/GB01/19863.9

Helleday T and Curtin NJ
Therapeutic Compounds (PARP inhibitors in homologous repair/BRCA defective cancer)
Patent Application Number PCT/GB2004/003183
Publication number WO 2005/012305 A2

Undergraduate Teaching

Supervision of final year project students

Postgraduate Teaching

Supervisor of PhD students
Module leader on web-based MSc in Oncology
Project supervisor for MRes students from Newcastle and York
Exchange programme for students at the University of Konstanz

• Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treatment Reviews 2012, 38(2), 89-100.
• Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
• Curtin NJ. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. Drug Discovery Today: Disease Models 2012, 9(2), e51-e58.
• Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today 2012, 17(5-6), 194-202.
• Shall S, Gaymes T, Farzaneh F, Curtin N, Mufti GJ. The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. In: Tulin, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2012, pp.239-66.
• Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012, 21(1), 20-26.
• Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine 2011, 17(7), 875-882.
• Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer 2011, 105(3), 372-381.
• Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of alpha(1)-Acid Glycoprotein. Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
• Mukhopadhyay A, Curtin NJ, Plummer ER, Edmondson RJ. PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine. BJOG 2011, 118(4), 429-432.
• Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal 2011, 436(3), 671–679.
• Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer 2011, 47(13), 2052-2059.
• Canan S, Maegley K, Curtin N. Strategies employed for the development of PARP inhibitors. In: Virag, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2011, pp.463-89.
• Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GCM, Leung HY, Curtin NJ, Robson CN. Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer. PLoS One 2011, 6(5), e20311.
• Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics 2011, 10(12), 2320-2329.
• Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Therapeutic Advances in Medical Oncology 2011, 3(6), 257-267.
• Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. British Journal of Cancer 2011, 105(8), 1114-1122.
• Drew Y, Mulligan EA, Vong W, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. Journal of the National Cancer Institute 2011, 103(4), 334-346.
• Issaeva N, Thomas HD, Djurenovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research 2010, 70(15), 6268-6276.
• Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010,103 10 1588-1596.
• Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clinical Cancer Research 2010, 16(8), 2344-2351.
• Clapham KM, Rennison T, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Golding BT, Hardcastle IR, Newell DR, Cano C, Griffin RJ. Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK). In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• Cano C, Barbeau OR, Bailey C, Cockroft XL, Curtin NJ, Duggan H, Frigerio M, Golding B, Griffin RJ. DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry 2010,53 24 8498–8507.
• Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology 2010, 66(4), 807-812.
• Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. British Journal of Cancer 2010, 102(2), 342-350.
• Vormoor B, Foy KE, Curtin N, Clifford SC. Sensitisation of paediatric solid tumours to DNA-damaging chemotherapy by inhibition of DNA-dependent protein kinase (PRKDC). In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, Wang LZ, Hardcastle IR. Synthesis and biological evaluation of 5-substituted O-4-alkylpyrimidines as CDK2 inhibitors. Organic & Biomolecular Chemistry 2010, 8(10), 2397-2407.
• Cornell L, Munck JM, Budhisetiawan F, Newell DR, Bardos JI, Manas D, Curtin NJ, Reeves H. Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases. 2010, Boston, MA: Hepatology: Wiley-Blackwell.
• Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular Cancer Therapeutics 2009, 8(2), 407-414.
• Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research 2009, 15(4), 1241-1249.
• Mitchell J, Smith GCM, Curtin NJ. Poly(ADP-Ribose) Polymerase-1 and DNA-Dependent Protein Kinase Have Equivalent Roles in Double Strand Break Repair Following Ionizing Radiation. International Journal of Radiation: Oncology - Biology - Physics 2009, 75(5), 1520-1527.
• Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. British Journal of Cancer 2009, 101(2), 256-262.
• Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics 2009, 8(7), 1828-1837.
• Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?. Clinical Cancer Research 2009, 15(19), 6106-6112.
• Murr M, Cano C, Golding BT, Hardcastle IR, Hummersome M, Frigerio M, Curtin NJ, Menear K, Richardson C, Smith G, Griffin R. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic and Medicinal Chemistry Letters 2008, 18(17), 4885-4890.
• Plummer ER, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin NJ, Boddy AV, McHugh P, Newell DR, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert AH. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clinical Cancer Research 2008, 14(23), 7917-7923.
• Scrace SF, Kierstan P, Borgognoni J, Wang LZ, Denny S, Wayne J, Bentley C, Cansfield AD, Jackson PS, Lockie AM, Curtin NJ, Newell DR, Williamson DS, Moore JD. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 2008,7 24 3898-3907.
• Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anti-Cancer Agents in Medicinal Chemistry 2007. , 7(5), 515-523.
• Thomas HD, Calabrese CR, Batey M, Canan S, Hostomsky Z, Kyle S, Maegley K, Newell DR, Skalitzky D, Wang L, Webber SE, Curtin NJ. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics 2007, 6(3), 945-956.
• Hollick J, Rigoreau L, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone M, Menear K, Martin N, Matthews I, Newell DR, Ord R, Richardson C, Smith G, Griffin RJ. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. Journal of Medicinal Chemistry 2007,50 8 1958-1972.
• Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic and Biomolecular Chemistry 2007, 5(10), 1577-1585.
• Rigas AC, Robson CN, Curtin NJ. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007, 26(55), 7611-7619.
• Curtin NJ. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opinion on Therapeutic Targets 2007. ,11 6 783-799.
• Zhao Y, Thomas HD, Batey M, Cowell I, Richardson C, Griffin RJ, Calvert AH, Newell DR, Smith G, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Research 2006, 66(10), 5354-5362.
• Griffin RJ, Henderson A, Curtin NJ, Echalier A, Endicott J, Hardcastle IR, Newell DR, Noble M, Wang L, Golding BT. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. Journal of the American Chemical Society 2006, 128(18), 6012-6013.
• Hardcastle I, Cockcroft X, Curtin NJ, El-Murr M, Leahy JJJ, Stockley M, Golding BT, Rigoreau L, Richardson C, Smith G, Griffin RJ. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. Journal of Medicinal Chemistry 2005,48 24 7829-7846.
• Fishel M, Newell D, Griffin R, Davison R, Wang L, Curtin NJ, Zuhowski E, Kasza K, Egorin M, Moschel R, Dolan M. Effect of cell cycle inhibition on cisplatin-induced cytotoxicity. Journal of Pharmacology and Experimental Therapeutics 2005,312 1 206-213.
• Hardcastle I, Ahmed S, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin R, Guyenne S, Hutton C, Källblad P, Kemp S, Kitching M, Newell D, Norbedo S, Northen J, Reid R, Saravanan K, Willems H, Lunec J. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorganic and Medicinal Chemistry Letters 2005,15 5 1515-1520.
• Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005, 7(4), 1-20.
• Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005. ,7 4 1-20.
• Pennati M, Campbell AJ, Curto M, Binda M, Cheng Y, Wang L, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IR, Henderson A, Zaffaroni N, Newell DR. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation. Molecular Cancer Therapeutics 2005,4 9 1328-1337.
• Bryant H, Schultz N, Thomas HD, Parker K, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035), 913-917.
• Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clinical Cancer Research 2005, 11(9), 3402-3409.
• Smith LM, Willmore E, Austin C, Curtin NJ. The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clinical Cancer Research 2005,11 23 8449-8457.
• Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96(1), 56-67.
• Tikhe J, Webber S, Hostomsky Z, Maegley K, Ekkers A, Li J, Yu X, Almassy R, Kumpf R, Boritzki T, Zhang C, Calabrese C, Curtin NJ, Kyle S, Thomas HD, Wang L, Calvert AH, Golding B, Griffin RJ, Newell DR. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2004, 47(22), 5467-5481.
• Veuger SJ, Curtin NJ, Smith GCM, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004, 23(44), 7322–7329.
• Veuger SJ, Curtin NJ, Smith G, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004,23 44 7322-7329.
• Hickson, I., Zhao, Y., Richardson, C., Green, S., Martin, N., Orr, A., Reaper, P., Jackson, S., Curtin, N.J., Smith, G. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Research 2004, 64(24), 9152-9159.
• Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury, P., Menyerol, J., Mesguiche, V., Newell, D.R., Noble, M., Pratt, D., Wang, L., Whitfield, H.J. N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. Journal of Medicinal Chemistry 2004, 47(15), 3710-3722.
• Curtin NJ, Wang L, Yiakouvaki A, Kyle S, Arris C, Canan-Koch S, Webber S, Durkacz BW, Calvert AH, Hostomsky Z, Newell DR. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells. Clinical Cancer Research 2004, 10(3), 881-889.
• White, A., Curtin, N.J., Eastman, B., Golding, B.T., Hostomsky, Z., Kyle,S., Li, J., Maegley, K., Skalitzky, D., Webber, S., Yu, X., Griffin, R.J. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2004, 14(10), 2433-2437.
• Curtin, N., Barlow, H., Bowman, K., Calvert, A. H., Davison, R., Golding, B., Huang, B., Loughlin, P., Newell, D., Smith, P., Griffin, R. Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein. Journal of Medicinal Chemistry 2004, 47(20), 4905-4922.
• Mesguiche, V, Parsons, R.J., Arris, C.E., Bentley, J., Boyle, F., Curtin, N.J., Davies, T.G., Endicott, J., Gibson, A., Golding, B., Griffin, R.J., Jewsbury, P., Johnson, L.N., Newell, D.R., Noble, M.E.M., Wang, L., Hardcastle, I.R. 4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters 2003, 13(2), 217-222.
• Calabrese C, Batey M, Thomas HD, Durkacz B, Wang L, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies. Clinical Cancer Research 2003, 9(7), 2711-2718.
• Veuger, S., Curtin, N.J., Richardson, C., Smith, G., Durkacz, B.W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Research 2003, 63(18), 6008-6015.
• Sayle, K., Bentley, J., Boyle, F., Calvert, A. H., Cheng, Y., Curtin, N. J., Endicott, J., Golding, B., Hardcastle, I., Jewsbury, P., Mesguiche, V., Newell, D. R., Noble, M., Parsons, R., Pratt, D., Wang, L., Griffin, R. J. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters 2003, 13(18), 3079-3082.
• Skalitzky, D., Marakovits, J., Maegley, K., Ekker, A., Yu, X., Hostomsky, Z., Webber, S., Eastman, B., Almassy, R., Li, J., Curtin, N. J., Newell, D. R., Calvert, A. H., Griffin, R. J., Golding, B. T. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. Journal of Medicinal Chemistry 2003, 46(2), 210-213.
• Northen J, Boyle F, Clegg W, Curtin NJ, Edwards A, Griffin R, Golding B. Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido-[5,4-d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines. Journal of the Chemical Society. Perkin Transactions 1 2002,2 1 108-115.
• Monks, N., Blakey, D., East, S., Dowell, R., Calvete, J., Curtin, N.J., Arris, C.E., Newell, D.R. DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. European Journal of Cancer 2002, 38(11), 1543-1552.
• Koch SSC, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li JK, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. Journal of Medicinal Chemistry 2002, 45(23), 4961-4974.
• Gibson A, Arris CE, Bentley J, Boyle F, Curtin NJ, Davies T, Endicott J, Golding BT, Grant S, Griffin R, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J., Whitfield, H.J. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives. Journal of Medicinal Chemistry 2002, 45(16), 3381-3393.
• Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology 2002, 9(10), 745-749.
• Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53 status on cellular sensitivity to antifolate drugs. Clinical Cancer Research 2001, 7(7), 2114-2123.
• Bowman, K. J., Newell, D. R., Calvert, A. H., Curtin, N. J. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. British Journal of Cancer 2001, 84(1), 106-112.
• Marshman, E., Taylor, G., Thomas, H., Newell, D.R., Curtin, N.J. Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole. Biochemical Pharmacology 2001, 61(4), 477-484.
• Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clinical Cancer Research 2001, 7(7), 2105-2113.
• Monks, N., Blakey,D., Curtin, N.J., East, S., Heuze, A., Newell, D.R. Induction of apoptosis by the ADEPT agent ZD2767: Comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. British Journal of Cancer 2001, 85(5), 764-771.
• Curtin, N.J., Hughes, A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncology 2001. , 2(5), 298-306.
• Lu, X., Errington, J., Chen, V., Curtin, N. J., Boddy, A. V., Newell, D. R. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clinical Cancer Research 2000, 6(1), 271-277.
• Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT). British Journal of Cancer 2000, 83(2), 267-269.
• Smith, P., Marshman, E., Newell, D.R., Curtin, N.J. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. British Journal of Cancer 2000, 82(4), 924-930.
• Arris, C. E., Boyle, F., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., Jewsbury, P., Johnson, L., Lawrie, A., Newell, D. R., Noble, M., Sausville, E., Schultz, R., Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
• Delaney, C.A., Wang, L., Kyle, S., White, A.W., Calvert, A.H., Curtin, N.J., Durkacz, B.W., Hostomsky, Z, Newell, D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical Cancer Research 2000, 6(7), 2860-2867.
• Griffin, R. J., Arris, C. E., Bleasdale, C. , Boyle, F., Calvert, A. H., Curtin, N. J., Dalby, C., Kanugula, S., Lembicz, N., Newell, D. R., Pegg, A., Golding, B. T. Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine. Journal of Medicinal Chemistry 2000, 43(22), 4071-4083.
• White, A.W., Almassy, R., Calvert, A.H., Curtin, N.J., Griffin, R.J., Hostomsky, Z., Maegley, K., Newell, D.R., Srinivasan, S, Golding, B.T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2000, 43(22), 4084-4097.
• Barlow, H. C., Bowman, K. J., Curtin, N. J., Calvert, A. H., Golding, B. T., Huang, B., Loughlin, P. J., Newell, D. R., Smith, P. G., Griffin, R. J. Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP). Bioorganic and Medicinal Chemistry Letters 2000, 10(6), 585-589.
• Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research 2000, 6, 328.
• Curtin, N.J., Turner, D.P. Dipyridamole-mediated reversal of multidrug resistance in MRP over- expressing human lung carcinoma cells in vitro. European Journal of Cancer 1999, 35(6), 1020-1026.
• Curtin, N.J., Bowman, K., Turner, R., Huang, B., Loughlin, P., Calvert, A.H., Golding, B.T., Griffin, R.J., Newell, D.R. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding. British Journal of Cancer 1999, 80(11), 1738-1746.
• Smith, P.G., Marshman, E., Calvert, A., Newell, D.R., Curtin, N.J. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. Seminars in Oncology 1999, 26(2), 63-67.
• Marshman, E., Newell, D.R., Calvert, A.H., Dickinson, A., Patel, H., Campbell, F., Curtin, N.J. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro. Clinical Cancer Research 1998, 4(11), 2895-2902.
• Bowman, J., White, A.W., Golding, B.T., Griffin, R.J., Curtin, N.J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. British Journal of Cancer 1998, 78(10), 1269-1277.
• Griffin, R. J., Srinivasan, S., Bowman, K., Calvert, A. H., Curtin, N. J., Newell, D. R., Pemberton, L. C., Golding, B. T. Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). Journal of Medicinal Chemistry 1998, 41(26), 5247-5256.
• Turner, R., Aherne, G., Curtin, N.J. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. British Journal of Cancer 1997, 76(10), 1300-1307.
• Turner, R., Curtin, N.J. Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells. British Journal of Cancer 1996, 73(7), 856-860.
• Arris, C. E., Bleasdale, C., Boyle, F. T., Calvert, A. H., Curtin, N. J., Dalby, C., Golding, B. T., Griffin, R. J., Lembicz, N., Lunn, J. M., Major, G. N., Newell, D. R. Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.. Abstracts of Papers of the American Chemical Society 1996, 212(1), 99-TOXI.
• Griffin, R.J., Srinivasan, S., White, A.W., Bowman, K., Calvert, A.H., Curtin, N.J., Newell, D.R., Golding, B.T. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase. Pharmaceutical Sciences 1996, 2(1), 43-47.
• Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy. Biochimie 1995, 77(6), 408-422.
• Arris, C. E., Bleasdale, C., Calvert, A. H., Curtin, N. J., Dalby, C., Golding, B. T., Griffin, R. J., Lunn, J. M., Major, G. N., Newell, D. R. Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines). Anti-Cancer Drug Design 1994, 9(5), 401-408.
• Curtin, N. J., Harris, A. L., Aherne, G. W. Mechanism of cell-death following thymidylate synthase inhibition - 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth-inhibition following exposure to CB3717 and dipyridamole.. Cancer Research 1991, 51(9), 2346-2352.
• Curtin NJ, Newell DR, Harris AL. Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.. Biochemical Pharmacology 1989, 38(19), 3281-8.
• Piall, E. M., Curtin, N. J., Aherne, G. W., Harris, A. L., Marks, V. The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhabited cells. Analytical Biochemistry 1989, 177(2), 347-352.
• Curtin NJ, Harris AL. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.. Biochemical Pharmacology 1988, 37(11), 2113-20.
• Bassendine MF, Curtin NJ, Loose H, Harris AL, James OF. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.. Journal of Hepatology 1987, 4(3), 349-56.
• CURTIN NJ, HARRIS AL. POTENTIATION OF CB3717 TOXICITY BY DIPYRIDAMOLE IN A549 CELLS. In: BRITISH JOURNAL OF CANCER. 1987.
• Curtin NJ, Harris AL, James OFW, Bassendine MF. Inhibition of the growth of human hepatocellular-carcinoma invitro and in athymic mice by a quinazoline inhibitor of thymidylate suntjase, CB3717. British Journal of Cancer 1986, 53(3), 361-368.
• CURTIN N, HARRIS AL, JAMES OFW, BASSENDINE MF. A NEW QUINAZOLINE ANTIFOLATE DRUG CB3717 WHICH INHIBITS THE GROWTH OF HUMAN-LIVER CANCER-CELLS IN ATHYMIC MICE, CELL-CULTURE AND PATIENTS. In: BRITISH JOURNAL OF CANCER. 1984.
• CURTIN NJ, INCE PG, GAUNT KL, FOWLER MJF, JAMES OFW, BASSENDINE MF. ESTABLISHMENT OF A CELL-LINE (PLC/NUT/1) CONTAINING INTEGRATED HEPATITIS-B VIRUS (HBV) DNA FROM A HORMONE ASSOCIATED HUMAN PRIMARY LIVER-CELL CANCER. In: GUT. 1984.
• Curtin NJ, Snell K. Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo. British Journal of Cancer 1983, 48(4), 495-505.
• Curtin NJ, Snell K. Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo. Biochemical Society Transactions 1980, 8(1), 94.
• Margison GP, Curtin NJ, Snell K, Craig AW. Effect of chronic N,N-diethylnitrosamine on the excision of O⁶-ethylguanine from rat liver DNA. British Journal of Cancer 1979, 40(5), 809-813.